Mumbai-headquartered manufacturer of bulk-drug intermediates and APIs (Metformin HCL, Mefenamic Acid, Doxophylline) with a single plant at Tarapur MIDC, Maharashtra, also importing solvents and chemicals.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 23 | 23 | 25 | 25 | 28 | 28 | 28 | 28 |
| Reserves | 69 | 75 | 88 | 92 | 105 | 110 | 120 | 122 |
| Borrowings | 18 | 18 | 14 | 38 | 31 | 35 | 51 | 50 |
| Other Liabilities | 84 | 116 | 117 | 136 | 139 | 117 | 94 | 97 |
| Total Liabilities | 194 | 233 | 245 | 291 | 303 | 291 | 294 | 297 |
| AssetsFixed Assets | 12 | 14 | 14 | 14 | 13 | 16 | 25 | 26 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Other Assets | 181 | 218 | 230 | 277 | 289 | 272 | 267 | 269 |
| Total Assets | 194 | 233 | 245 | 291 | 303 | 291 | 294 | 297 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1 | 3 | 5 | 0 | -1 | -3 | 10 | 10 |
| Cash from Investing | -1 | -1 | -3 | -3 | 0 | -2 | -6 | -12 |
| Cash from Financing | -2 | -2 | -2 | 2 | 1 | 6 | -4 | 2 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -1 | 2 | 3 | -2 | -2 | -4 | 5 | -2 |
| FCF Margin | — | — | — | — | — | — | — | — |
An earnings-based reverse DCF needs positive, normalized profits. This business doesn't have them yet, so any 'fair value' would be fiction.
AAREYDRUGS · LOSS_MAKING
Guides on how to read this kind of business and the numbers that matter.